Léčba kastračně rezistentního karcinomu prostaty enzalutamidem trvající 4 roky

Download PDF English version

Authors: G. Gilles Natchagande ¹; Vinh-Hung Vincent ²
Authors‘ workplace: Teaching University Hospital of Cotonou, Cotonou, Benin ¹; University Hospital of Martinique, Fort-de-France, Martinique, France ²
Published in: Klin Onkol 2021; 34(1): 69-72
Category: Case Report
doi: https://doi.org/10.48095/ccko202169

Overview

Východiska: Léčba metastatického kastračně rezistentního karcinomu prostaty zahrnuje antiandrogenní terapii, kam patří enzalutamid. U starších pacientů je někdy obtížné užívat doporučenou dávku 160 mg/den kvůli zátěži komorbiditami. Užitečnost snížené dávky je stále nejasná. Metody: Popisujeme případ prvního pacienta, nyní ve věku 87 let, který měl progresivní karcinom prostaty a více než 4 roky byl léčen 25% doporučené dávky.

Výsledky: Nejpozoruhodnějším zjištěním je, že se nic mimořádného nestalo. Došlo k odpovědi na léčbu bez výrazné toxicity. Sledování tohoto pacienta je poklidné jak z hlediska karcinomu prostaty, tak z hlediska celkového zdravotního stavu.

Závěr: Opatrné dávkování může starším pacientům přinést dlouhodobý prospěch.

Klíčová slova:

karcinom prostaty – novotvary prostaty – kastračně rezistentní – užívání snížených dávek léčiva – účinnost léčby – výsledky léčby – enzalutamid

Sources

1. Sternberg CN. Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer. Future Oncol 2019; 15 (13): 1437–1457. doi: 10.2217/fon-2018-0940.

2. Richter I, Dvorak J, Hejzlarova V et al. Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy. Klin Onkol 2016; 29 (2): 127–132. doi: 10.14735/amko2016127.

3. Benoist GE, van Oort IM, Smeenk S et al. Drug-drug interaction potential in men treated with enzalutamide: Mind the gap. Br J Clin Pharmacol 2018; 84 (1): 122–1229. doi: 10.1111/bcp.13425.

4. Terada N, Akamatsu S, Okada Y et al. Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study. Int J Clin Oncol 2016; 21 (6): 1155–1161. doi: 10.1007/s10147-016-1004-y.

5. Vinh-Hung V, Natchagande G, Joachim C et al. Low dose enzalutamide in the late-elderly patient (≥75 years old) presenting with metastatic castration-resistant prostate cancer. [in press]. Clin Genitourin Cancer 2020. doi: 10.1016/j.clgc.2020.03.019.

6. Xtandi prescribing information, version 12/2019. [online]. Available from: https: //www.accessdata.fda.gov/drugsatfda_docs/label/2019/203415s015lbl.pdf.

7. Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375 (9724): 1437–1446. doi: 10.1016/S0140-6736 (10) 60172-9.

8. Kawahara T, Miyoshi Y, Yao M et al. The achievement of long-term CRPC control in a patient with enzalutamide-induced nausea and fatigue after overcoming the adverse events with a temporary drug holiday. Case Rep Oncol 2019; 12 (2): 568-572. doi: 10.1159/000501849.

9. Strobbe G, Pannier D, Villain A et al. First-time prescription of enzalutamide in a patient treated with fluindione and digoxin: serial drug interactions. Acta Oncol 2019; 58 (8): 1167–1169. doi: 10.1080/0284186X.2019.1606936.

10. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371 (5): 424–433. doi: 10.1056/NEJMoa1405095.

11. Beer TM, Armstrong AJ, Rathkopf D et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol 2017; 71 (2): 151–154. doi: 10.1016/j.eururo.2016.07.032.

12. Armstrong AJ, Lin P, Higano CS et al. Prognostic association of prostate-specific antigen decline with clinical outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide in a randomized clinical trial. Eur Urol Oncol 2019; 2 (6): 677–684. doi: 10.1016/j.euo.2018.11.005.

13. Joshua AM, Shore ND, Saad F et al. Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America. Prostate 2015; 75 (8): 836–844. doi: 10.1002/pros.22965.

14. Beardo P, Osman I, San Jose B et al. Safety and outcomes of new generation hormone-therapy in elderly chemotherapy-naive metastatic castration-resistant prostate cancer patients in the real world. Arch Gerontol Geriatr 2019; 82: 179–185. doi: 10.1016/j.archger.2019.02.008.

15. Zhu X, Wu S. Increased risk of hypertension with enzalutamide in prostate cancer: a meta-analysis. Cancer Invest 2019; 37 (9): 478–488. doi: 10.1080/07357907.2019. 1670203.

16. Lu-Yao G, Nikita N, Keith SW et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities. Eur Urol 2019; 77 (2): 158–166. doi: 10.1016/j.eururo.2019.07.031.

17. De Nunzio C, Lombardo R, Tema G et al. Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta--analysis of registrational phase III studies. Prostate Cancer Prostatic Dis 2019; 23 (2): 199–206. doi: 10.1038/s41391-019-0182-x.

18. Richter I, Dvorak J, Bartos J. Docetaxel-cabazitaxel-enzalutamide versus docetaxel-enzalutamide in patients with metastatic castration-resistant prostate cancer. Klin Onkol 2017; 30 (4): 289–293. doi: 10.14735/amko2017 289.

19. Richter I, Dvorak J, Bartos J. Options of chemotherapy in the treatment of prostate cancer. Klin Onkol 2017; 30 (1): 28–33. doi: 10.14735/amko201728.

20. Ondrus D, Ondrusova M. Management of patients with castration-resistant metastatic prostate cancer. Klin Onkol 2015; 28 (1): 24–29. doi: 10.14735/amko201524.

21. Hanus M, Matouskova M, Dusek L. Prostate carcinoma. Current dilemma of urooncology. How to help the needed and not to harm the others. Klin Onkol 2013; 26 (3): 170–178. doi: 10.14735/amko2013170.

22. Matouskova M. Prostate cancer. Klin Onkol 2008; 21 (5): 280–287.